Risk factors for iron metabolic disorders in newly diagnosed B-chronic lymphocytic leukemia patients

Hiba Muwafaq Saleem; Muthanna Mohammed Awad; Alaa Fadhil Alwan

doi:10.53730/ijhs.v6nS7.12702

Authors

Hiba Muwafaq Saleem
h.m.saleem@uoa.edu.iq
Department of Biology, College of Sciences , University Of Anbar, Ramadi, Iraq Department of Medical Laboratory Techniques , Al-Maarif University college, Ramadi Iraq
Muthanna Mohammed Awad Department of Biology, College of Education for Pure Sciences, University Of Anbar, Ramadi, Iraq
Alaa Fadhil Alwan Department of clinical Hematology , The National center of Hematology, Mustansiriyah University, Baghdad, Iraq

Keywords:

Hormonal alterations, Hypoxia, Lymphadenopathy

Abstract

Due to the importance of increasing the incidence conditions of B cell chronic lymphocytic leukemia (B-CLL) that requiring accurate knowledge of the biology behind the pathogenesis and risks of this disease of each individual patient, this study was designed to investigate if hormonal alterations such as Hepcidin, Erythropoietin, and oxidant-antioxidant status may be useful in the understanding of B-CLL development in addition the relationship of these parameters with anemia in advance clinical stage in newly diagnosed patients with B-CLL. This study was conducted on 60 newly diagnosed patients with B-CLL and 30 control group .The socio-demographic information including (age and sex) and clinical data were collected for the period from 20 February until 25 December 2021. The result of the present study showed that out of the 60 newly diagnosed B-CLL patients, 39 was male and 21 was females, with the mean age ( 64.04 ± 5.6 ) years and out of the 30 controls group ,12 was males and 18 was females with the mean age of ( 63.33 ± 4.70) years .therefore, it was a higher prevalence p value ≤0.05 of newly diagnosed B-CLL patients in males (65.0 %) compare to females (35.0 % ).

Downloads

Download data is not yet available.

References

El-Sharkawy, E. A., Sayed, D. M., Abdel Hamid, W. M., Moness, H., & Yusuf, S. M. (2022). Demographic data in patients with Chronic Lymphocytic Leukemia. Minia Journal of Medical Research, 260-261.‏

Jakšić, B., Pejša, V., Ostojić-Kolonić, S., Kardum-Skelin, I., Bašić-Kinda, S., Coha, B., ... & Nemet, D. (2018). Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017. Acta clinica Croatica, 57(1.), 190-215.‏

Wang, F., Lv, H., Zhao, B., Zhou, L., Wang, S., Luo, J., ... & Shang, P. (2019). Iron and leukemia: new insights for future treatments. Journal of Experimental & Clinical Cancer Research, 38(1), 1-17.‏

Xu, Y., Alfaro‐Magallanes, V. M., & Babitt, J. L. (2021). Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders. British Journal of Haematology, 193(5), 882-893.‏

Wojciechowska, M., Wisniewski, O. W., Kolodziejski, P., & Krauss, H. (2021). Role of hepcidin in physiology and pathophysiology. Emerging experimental and clinical evidence. Journal of Physiology and Pharmacology: an Official Journal of the Polish Physiological Society, 72(1).‏

Lombardero, M., Kovacs, K., & Scheithauer, B. W. (2011). Erythropoietin: a hormone with multiple functions. Pathobiology, 78(1), 41-53.‏

Dahl, S. L., Bapst, A. M., Khodo, S. N., Scholz, C. C., & Wenger, R. H. (2022). Fount, fate, features, and function of renal erythropoietin-producing cells. Pflügers Archiv-European Journal of Physiology, 1-15.‏

Mauro, F. R., Gentile, M., & Foa, R. (2002). Erythropoietin and chronic lymphocytic leukemia. Reviews in Clinical and Experimental Hematology, 21-31.‏

Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., ... & Kipps, T. J. (2018). iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, The Journal of the American Society of Hematology, 131(25), 2745-2760.‏

Jakšić, B., Vitale, B., Hauptmann, E., Planinc-Peraica, A., Ostojic, S., & Kusec, R. (1991). The roles of age and sex in the prognosis of chronic leukaemias. A study of 373 cases. British journal of cancer, 64(2), 345-348.‏

Porter, R. S., & Kaplan, J. L. (2011). The Merck Manual of Diagnosis and Therapy Nineteenth Edition. Merck sharp & Dohme corp., A subsidiary of Merck & Co. Inc., Whithouse station, 2868.‏

Yamamoto, J. F., & Goodman, M. T. (2008). Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes & Control, 19(4), 379-390.‏

Zwiebel, J. A., & Cheson, B. D. (1998, February). Chronic lymphocytic leukemia: staging and prognostic factors. In Seminars in oncology (Vol. 25, No. 1, pp. 42-59).‏

Rai, K. R., & Keating, M. J. (2006). Clinical manifestation and diagnosis of chronic lymphocytic leukemia. UpToDate, 107, 1294.‏

Binet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., ... & Gremy, F. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48(1), 198-206.‏

Vela, D., & Vela-Gaxha, Z. (2018). Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications. Experimental & molecular medicine, 50(2), e436-e436.‏

Arvedson, T. C., Li, H., Rose, M. J., Wang, O., & Sasu, B. J. (2008). Evaluation of serum hepcidin concentrations in cancer and leukemia patients. Journal of Clinical Oncology, 26(15_suppl), 20581-20581.‏

Sangkhae, V., & Nemeth, E. (2017). Regulation of the iron homeostatic hormone hepcidin. Advances in nutrition, 8(1), 126-136.‏

Saleem, H. M., Muhammed, T. M., Al-Hetty, H. R. A. K., & Salman, D. A. (2022). Physiological, hematological and some biochemical alterations during pregnancy. International Journal of Health Sciences, 6(S6), 7156–7169.

Camaschella, C., Nai, A., & Silvestri, L. (2020). Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica, 105(2), 260.‏

Torti, S. V., & Torti, F. M. (2013). Iron and cancer: more ore to be mined. Nature Reviews Cancer, 13(5), 342-355.‏

Capalbo, S., Battista, C., Delia, M., Ciancio, A., De Santis, G., Dargenio, M., ... & Liso, V. (2002). Evaluation of tumor necrosis factor-α and erythropoietin serum levels in B-cell chronic lymphocytic leukemia patients with anemia. Acta haematologica, 108(2), 84-89.‏

Beguin, Y., Lampertz, S., Bron, D., & Fillet, G. (1996). Serum erythropoietin in chronic lymphocytic leukaemia. British journal of haematology, 93(1), 154-156.‏

Goldwasser, E. (1984). Erythropoietin and its mode of action. Blood Cells, 10(2-3), 147-162.‏

Katz, O., Barzilay, E., Skaat, A., Herman, A., Mittelman, M., & Neumann, D. (2005). Erythropoietin induced tumour mass reduction in murine lymphoproliferative models. Acta haematologica, 114(3), 177-179.‏

‏[26] Koskenkorva-Frank, T. S., Weiss, G., Koppenol, W. H., & Burckhardt, S. (2013). The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radical Biology and Medicine, 65, 1174-1194.‏

De Santis, M. C., Porporato, P. E., Martini, M., & Morandi, A. (2018). Signaling pathways regulating redox balance in cancer metabolism. Frontiers in oncology, 8, 126.‏

Zhevak, T., Shelekhova, T., Chesnokova, N., Tsareva, O., Chanturidze, A., Litvitsky, P., ... & Budnik, I. (2020). The relationship between oxidative stress and cytogenetic abnormalities in B-cell chronic lymphocytic leukemia. Experimental and Molecular Pathology, 116, 104524.‏

Bakan, N., Taysi, S., Yilmaz, Ö., Bakan, E., Kuşkay, S., Uzun, N., & Gündoğdu, M. (2003). Glutathione peroxidase, glutathione reductase, Cu–Zn superoxide dismutase activities, glutathione, nitric oxide, and malondialdehyde concentrations in serum of patients with chronic lymphocytic leukemia. Clinica Chimica Acta, 338(1-2), 143-149.‏

Oltra, A. M., Carbonell, F., Tormos, C., Iradi, A., & Sáez, G. T. (2001). Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic lerkenia. Free Radical Biology and Medicine, 30(11), 1286-1292.‏

Salimi, A., Roudkenar, M. H., Sadeghi, L., Mohseni, A., Seydi, E., Pirahmadi, N., & Pourahmad, J. (2016). Selective anticancer activity of acacetin against chronic lymphocytic leukemia using both in vivo and in vitro methods: key role of oxidative stress and cancerous mitochondria. Nutrition and cancer, 68(8), 1404-1416.‏

D’Arena, G., Seneca, E., Migliaccio, I., De Feo, V., Giudice, A., La Rocca, F., ... & Ruggieri, V. (2019). Oxidative stress in chronic lymphocytic leukemia: still a matter of debate. Leukemia & Lymphoma, 60(4), 867-875.‏

Saleem, H. M., Awad, M. M., & Alwan, A. F. (2022). The correlation between CD200 expression and oxidant-antioxidant status in newly diagnosed B-chronic lymphocytic leukemia patients. International Journal of Health Sciences, 6(S9), 1–13.

D'arena, G., Vitale, C., Perbellini, O., Coscia, M., La Rocca, F., Ruggieri, V., ... & Iorio, E. L. (2017). Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. European journal of haematology, 99(4), 306-314.‏

Collado, R., Ivars, D., Oliver, I., Tormos, C., Egea, M., Miguel, A., ... & Carbonell, F. (2014). Increased oxidative damage associated with unfavorable cytogenetic subgroups in chronic lymphocytic leukemia. BioMed Research International, 2014.‏

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938

Zelen, I., Djurdjevic, P., Popovic, S., Stojanovic, M., Jakovljevic, V., Radivojevic, S., ... & Arsenijevic, N. (2010). Antioxidant enzymes activities and plasma levels of oxidative stress markers in B-chronic lymphocytic leukemia patients. J buon, 15(2), 330-336.‏

Hwang, A. B., & Lee, S. J. (2011). Regulation of life span by mitochondrial respiration: the HIF-1 and ROS connection. Aging (Albany NY), 3(3), 304.‏

Kumar, S., Yedjou, C. G., & Tchounwou, P. B. (2014). Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells. Journal of experimental & clinical cancer research, 33(1), 1-12.‏